Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) receptor , is showing promising outcomes in initial patient trials . Ongoing research indicates https://orangebookmarks.com/story21427343/retatrutide-emerging-research-and-potential-medical-roles